Clinical Trial Update: Phase III Radium 223 mCRPC-PEACE III [Phase 3]

View source ↗

Summary

Phase III Radium-223 mCRPC-PEACE III trial for metastatic castration-resistant prostate cancer is currently listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride) (radium-223 dichloride)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING